Table 1 Demographic and baseline characteristics
MET + SU N = 4655 | MET + DPP-4i N = 2899 | MET + SGLT-2i N = 441 | Other* N = 1102 | Overall N = 9097 | |
|---|---|---|---|---|---|
Male, n (%) | 2679 (57.6) | 1704 (58.8) | 266 (60.3) | 551 (50.0) | 5200 (57.2) |
Age (years), mean (SD) | 61.54 (12.97) | 60.81 (12.34) | 55.05 (10.14) | 62.81 (14.85) | 61.15 (12.98) |
<50 | 892 (19.2%) | 544 (18.8%) | 128 (29.0%) | 210 (19.1%) | 1774 (19.5%) |
50 to <60 | 1150 (24.7%) | 805 (27.8%) | 165 (37.4%) | 241 (21.9%) | 2361 (26.0%) |
60 to <70 | 1291 (27.7%) | 842 (29.0%) | 119 (27.0%) | 275 (25.0%) | 2527 (27.8%) |
≥70 | 1322 (28.4%) | 708 (24.4%) | 29 (6.6%) | 376 (34.1%) | 2435 (26.8%) |
HbA1c (%), mean (SD) | 9.19 (1.88) | 8.75 (1.50) | 9.07 (1.58) | 8.72 (1.91) | 8.98 (1.77)† |
<7 | 283 (6.2%) | 147 (5.1%) | 20 (4.6%) | 164 (15.2%) | 614 (6.9%) |
7 to <8 | 971 (21.3%) | 829 (28.8%) | 100 (23.0%) | 276 (25.5%) | 2176 (24.3%) |
8 to <9 | 1245 (27.3%) | 923 (32.1%) | 120 (27.7%) | 254 (23.5%) | 2542 (28.4%) |
9 to <10 | 783 (17.2%) | 468 (16.3%) | 84 (19.4%) | 152 (14.1%) | 1487 (16.6%) |
10 to <11 | 491 (10.8%) | 244 (8.5%) | 54 (12.4%) | 92 (8.5%) | 881 (9.8%) |
≥11 | 787 (17.3%) | 266 (9.3%) | 56 (12.9%) | 144 (13.3%) | 1253 (14.0%) |
HbA1c (mmol/mol), mean (SD) | 77 (20.6) | 72 (16.4) | 76 (17.3) | 72 (20.9) | 75 (19.3)† |
BMI (kg/m2, mean (SD) | 31.78 (6.50) | 33.21 (6.56) | 36.56 (6.98) | 33.12 (7.93) | 32.64 (6.82)† |
<20 | 43 (0.9%) | 8 (0.3%) | 0 | 24 (2.2%) | 75 (0.8%) |
20 to <25 | 498 (10.9%) | 194 (6.8%) | 8 (1.8%) | 106 (9.8%) | 806 (9.0%) |
25 to <30 | 1457 (31.9%) | 795 (27.7%) | 65 (14.8%) | 273 (25.2%) | 2590 (28.9%) |
30 to <35 | 1366 (29.9%) | 887 (31.0%) | 129 (29.5%) | 301 (27.8%) | 2683 (30.0%) |
≥35 | 1208 (26.4%) | 982 (34.3%) | 236 (53.9%) | 379 (35.0%) | 2805 (31.3%) |
Weight (kg), mean (SD) | 90.97 (21.00) | 96.00 (21.50) | 107.30 (22.87) | 93.63 (25.55) | 93.70 (22.18)† |
<60 | 189 (4.1%) | 63 (2.2%) | 2 (0.5%) | 51 (4.7%) | 305 (3.4%) |
60 to <80 | 1227 (26.6%) | 578 (20.1%) | 40 (9.1%) | 298 (27.3%) | 2143 (23.8%) |
80 to <100 | 1837 (39.9%) | 1133 (39.3%) | 127 (28.9%) | 361 (33.1%) | 3458 (38.4%) |
100 to <120 | 954 (20.7%) | 728 (25.3%) | 166 (37.7%) | 232 (21.3%) | 2080 (23.1%) |
≥120 | 399 (8.7%) | 378 (13.1%) | 105 (23.9%) | 149 (13.7%) | 1031 (11.4%) |
Time since diagnosis (years), median (IQR) | 4.00 (1.57–7.20) | 4.25 (1.88–7.21) | 3.30 (1.47–5.55) | 4.64 (1.94–8.05) | 4.10 (1.70–7.22) |
<6 months | 542 (11.6%) | 237 (8.2%) | 40 (9.1%) | 74 (6.7%) | 893 (9.8%) |
6 months to <1 year | 283 (6.1%) | 174 (6.0%) | 35 (7.9%) | 68 (6.2%) | 560 (6.2%) |
1 to <3 years | 1076 (23.1%) | 658 (22.7%) | 129 (29.3%) | 250 (22.7%) | 2113 (23.2%) |
3 to <5 years | 839 (18.0%) | 591 (20.4%) | 104 (23.6%) | 194 (17.6%) | 1728 (19.0%) |
≥5 years | 1915 (41.1%) | 1239 (42.7%) | 133 (30.2%) | 516 (46.8%) | 3803 (41.8%) |
Time since initiation of first-line therapy (years), median (IQR) | 2.20 (0.72–4.65) | 2.62 (1.02–4.89) | 2.05 (0.85–4.02) | 2.30 (0.89–4.84) | 2.33 (0.85–4.72) |
<6 months | 953 (20.5%) | 427 (14.7%) | 71 (16.1%) | 171 (15.5%) | 1622 (17.8%) |
6 months to <1 year | 474 (10.2%) | 280 (9.7%) | 50 (11.3%) | 124 (11.3%) | 928 (10.2%) |
1 to <3 years | 1346 (28.9%) | 884 (30.5%) | 157 (35.6%) | 346 (31.4%) | 2733 (30.0%) |
3 to <5 years | 840 (18.1%) | 613 (21.2%) | 89 (20.2%) | 199 (18.1%) | 1741 (19.1%) |
≥5 years | 1042 (22.4%) | 695 (24.0%) | 74 (16.8%) | 262 (23.8%) | 2073 (22.8%) |